Arash Pakseresht

1.4k total citations · 1 hit paper
12 papers, 975 citations indexed

About

Arash Pakseresht is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Pharmacology. According to data from OpenAlex, Arash Pakseresht has authored 12 papers receiving a total of 975 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Endocrinology, Diabetes and Metabolism, 8 papers in Molecular Biology and 7 papers in Pharmacology. Recurrent topics in Arash Pakseresht's work include Diabetes Treatment and Management (11 papers), Metabolism, Diabetes, and Cancer (8 papers) and Pharmacology and Obesity Treatment (7 papers). Arash Pakseresht is often cited by papers focused on Diabetes Treatment and Management (11 papers), Metabolism, Diabetes, and Cancer (8 papers) and Pharmacology and Obesity Treatment (7 papers). Arash Pakseresht collaborates with scholars based in Denmark, United Kingdom and Canada. Arash Pakseresht's co-authors include Sue D. Pedersen, Louise Færch, Ole Kleist Jeppesen, Leigh Perreault, Iichiro Shimomura, Adie Viljoen, Thomas A. Wadden, Melanie J. Davies, Ildiko Lingvay and Julio Rosenstock and has published in prestigious journals such as The Lancet, Diabetes and Obesity.

In The Last Decade

Arash Pakseresht

11 papers receiving 947 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

2021 806 citations Melanie J. Davies, Louise Færch et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Arash Pakseresht Denmark	7	707	499	310	257	233	12	975
Altynai Satylganova Denmark	9	471 0.7×	342 0.7×	199 0.6×	246 1.0×	153 0.7×	12	780
Anna Koroleva Denmark	6	617 0.9×	498 1.0×	249 0.8×	254 1.0×	151 0.6×	12	863
Signe Olrik Rytter Wallenstein United States	5	537 0.8×	428 0.9×	245 0.8×	214 0.8×	130 0.6×	9	717
Louise Færch Denmark	7	720 1.0×	414 0.8×	279 0.9×	239 0.9×	240 1.0×	16	930
Trine Vang Skjøth Denmark	12	1.1k 1.6×	614 1.2×	384 1.2×	304 1.2×	344 1.5×	23	1.3k
Rafael Violante Ortíz Denmark	6	1.3k 1.8×	1.1k 2.2×	403 1.3×	635 2.5×	375 1.6×	11	1.8k
Christian R. Juhl Denmark	12	353 0.5×	258 0.5×	144 0.5×	278 1.1×	123 0.5×	26	816
Simon Birk Kjær Jensen Denmark	9	336 0.5×	248 0.5×	121 0.4×	270 1.1×	102 0.4×	15	666
Katherine H. Saunders United States	17	234 0.3×	246 0.5×	105 0.3×	394 1.5×	313 1.3×	35	854
Meera Shah United States	16	438 0.6×	114 0.2×	167 0.5×	376 1.5×	542 2.3×	38	1.0k

Countries citing papers authored by Arash Pakseresht

Since Specialization

Citations

This map shows the geographic impact of Arash Pakseresht's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arash Pakseresht with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arash Pakseresht more than expected).

Fields of papers citing papers by Arash Pakseresht

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arash Pakseresht. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arash Pakseresht. The network helps show where Arash Pakseresht may publish in the future.

Co-authorship network of co-authors of Arash Pakseresht

This figure shows the co-authorship network connecting the top 25 collaborators of Arash Pakseresht. A scholar is included among the top collaborators of Arash Pakseresht based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arash Pakseresht. Arash Pakseresht is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Davies, Melanie J., Louise Færch, Ole Kleist Jeppesen, et al.. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 397(10278). 971–984. 806 indexed citations breakdown →

Perreault, Leigh, Melanie J. Davies, Louise Færch, et al.. (2021). 82-OR: Effect of Semaglutide 2.4 mg on Glucose Metabolism and Body Weight in Adults with Overweight/Obesity and Type 2 Diabetes in the STEP 2 Trial. Diabetes. 70(Supplement_1). 1 indexed citations

Davies, Melanie J., Louise Færch, Ole Kleist Jeppesen, et al.. (2021). Efficacy and Safety of Semaglutide 2.4 MG Once-Weekly in Adults With Overweight or Obesity and Type 2 Diabetes (STEP 2). Journal of the Endocrine Society. 5(Supplement_1). A10–A11. 2 indexed citations

Wharton, Sean, et al.. (2020). Real‐world persistence with liraglutide 3.0 mg for weight management and the SaxendaCare® patient support program. Obesity Science & Practice. 6(4). 382–389. 6 indexed citations

Wharton, Sean, et al.. (2020). Weight loss and persistence with liraglutide 3.0 mg by obesity class in the real‐world effectiveness study in Canada. Obesity Science & Practice. 6(4). 439–444. 20 indexed citations

Hocking, Samantha, Sean Wharton, Arash Pakseresht, et al.. (2019). Real-world clinical effectiveness of liraglutide 3.0 mg for weight management in Canada. Obesity Research & Clinical Practice. 13(3). 251–251. 6 indexed citations

Wharton, Sean, et al.. (2019). Real‐World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada. Obesity. 27(6). 917–924. 58 indexed citations

Sharma, Arya M., André Bélanger, Marie‐France Langlois, et al.. (2019). Perceptions of barriers to effective obesity management in Canada: Results from the ACTION study. Clinical Obesity. 9(5). e12329–e12329. 59 indexed citations

Wharton, Sean, et al.. (2018). Real-World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada. Value in Health. 21. S246–S246. 2 indexed citations

10.

Heise, Tim, Thomas R. Pieber, Thomas Danne, et al.. (2016). Faster Onset and Greater Early Exposure and Glucose-Lowering Effect with Faster-Acting Insulin Aspart vs. Insulin Aspart: A Pooled Analysis in Subjects with Type 1 Diabetes. Canadian Journal of Diabetes. 40(5). S57–S57. 4 indexed citations

11.

Bowering, Keith, Christopher Case, John M. Harvey, et al.. (2016). Faster-Acting Insulin Aspart vs. Insulin Aspart in Basal-Bolus Therapy Improved Postprandial Glycemic Control in Uncontrolled T2D in the Onset® 2 Trial. Canadian Journal of Diabetes. 40(5). S57–S57. 4 indexed citations

12.

Russell‐Jones, David, Bruce W. Bode, Christophe De Block, et al.. (2016). Double-Blind Mealtime Faster-Acting Insulin Aspart vs. Insulin Aspart in Basal-Bolus Improves Glycemic Control in T1D: The Onset® 1 Trial. Canadian Journal of Diabetes. 40(5). S58–S58. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact